International Journal of General Medicine (Dec 2023)
Advances in the Study of MG53 in Cardiovascular Disease
Abstract
Shan-Mei Liu,1,* Qin Zhao,1,* Wen-Jun Li,2 Jian-Quan Zhao1 1Bayannur Hospital Department of Cardiology, Bayannur City, Inner Mongolia, 015000, People’s Republic of China; 2Tangshan Central Hospital, Tangshan, Hebei, 063008, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jian-Quan Zhao, Tel +13947818787, Email [email protected]: Cardiovascular diseases represent a global health crisis, and understanding the intricate molecular mechanisms underlying cardiac pathology is crucial for developing effective diagnostic and therapeutic strategies. Mitsugumin-53 (MG53) plays a pivotal role in cell membrane repair, has emerged as a multifaceted player in cardiovascular health. MG53, also known as TRIM72, is primarily expressed in cardiac and skeletal muscle and actively participates in membrane repair processes essential for maintaining cardiomyocyte viability. It promotes k-ion currents, ensuring action potential integrity, and actively engages in repairing myocardial and mitochondrial membranes, preserving cardiac function in the face of oxidative stress. This study discusses the dual impact of MG53 on cardiac health, highlighting its cardioprotective role during ischemia/reperfusion injury, its modulation of cardiac arrhythmias, and its influence on cardiomyopathy. MG53’s regulation of metabolic pathways, such as lipid metabolism, underlines its role in diabetic cardiomyopathy, while its potential to mitigate the effects of various cardiac disorders, including those induced by antipsychotic medications and alcohol consumption, warrants further exploration. Furthermore, we examine MG53’s diagnostic potential as a biomarker for cardiac injury. Research has shown that MG53 levels correlate with cardiomyocyte damage and may predict major adverse cardiovascular events, highlighting its value as a biomarker. Additionally, exogenous recombinant human MG53 (rhMG53) emerges as a promising therapeutic option, demonstrating its ability to reduce infarct size, inhibit apoptosis, and attenuate fibrotic responses. In summary, MG53’s diagnostic and therapeutic potential in cardiovascular diseases presents an exciting avenue for improved patient care and outcomes.Keywords: Mitsugumin-53, MG53, cardiovascular disease, cell membrane repair, ischemia/reperfusion
